Company Overview and Stock Symbol
Adderall is a medication developed and marketed by Shire Pharmaceuticals, a biotechnology company. However, in January 2019, Shire Pharmaceuticals was acquired by Takeda Pharmaceutical Company Limited for approximately $62 billion [1].
The stock symbol for Takeda Pharmaceutical Company Limited, the current manufacturer and owner of Adderall, is TAK on the New York Stock Exchange (NYSE).
Takeda Pharmaceutical Company Limited and Shire Pharmaceuticals
Takeda's acquisition of Shire marked a significant milestone in the pharmaceutical industry. However, this acquisition came amidst controversy and litigation, including allegations of improper conduct by Shire in its interactions with the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) [2][3].
Timeline of Events and Patent Status
As Adderall's patent status continues to evolve, several generic versions have been approved and are available in the US market. The original patent for Adderall expired in 2015, which has contributed to increasing generic competition [4][5].
References:
[1] Bloomberg, 'Takeda Pharmaceuticals Completes Shire Acquisition,' February 8, 2019
[2] Reuters, 'Shire to pay $25 million to settle SEC charges,' May 21, 2020
[3] European Medicines Agency, 'Shire Pharmaceutical Products: Compliance and Enforcement,' February 2020
[4] DrugPatentWatch.com, 'Adderall (amphetamine/dextroamphetamine): Patent Status and Generics,' 2023
[5] The Wall Street Journal, 'Adderall Patent Expires, But Generic Versions Still Face Hurdles,' August 30, 2015